162 related articles for article (PubMed ID: 21802945)
1. Synthesis of purine-scaffold fluorescent probes for heat shock protein 90 with use in flow cytometry and fluorescence microscopy.
Taldone T; Gomes-DaGama EM; Zong H; Sen S; Alpaugh ML; Zatorska D; Alonso-Sabadell R; Guzman ML; Chiosis G
Bioorg Med Chem Lett; 2011 Sep; 21(18):5347-52. PubMed ID: 21802945
[TBL] [Abstract][Full Text] [Related]
2. The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1.
Usmani SZ; Bona RD; Chiosis G; Li Z
J Hematol Oncol; 2010 Oct; 3():40. PubMed ID: 20977755
[TBL] [Abstract][Full Text] [Related]
3. Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2.
Gallerne C; Prola A; Lemaire C
Biochim Biophys Acta; 2013 Jun; 1833(6):1356-66. PubMed ID: 23485394
[TBL] [Abstract][Full Text] [Related]
4. Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71.
Taldone T; Zatorska D; Ochiana SO; Smith-Jones P; Koziorowski J; Dunphy MP; Zanzonico P; Bolaender A; Lewis JS; Larson SM; Chiosis G; Pillarsetty NV
J Labelled Comp Radiopharm; 2016 Mar; 59(3):129-32. PubMed ID: 26806023
[TBL] [Abstract][Full Text] [Related]
5. Radiosensitization of human lung cancer cells by the novel purine-scaffold Hsp90 inhibitor, PU-H71.
Segawa T; Fujii Y; Tanaka A; Bando S; Okayasu R; Ohnishi K; Kubota N
Int J Mol Med; 2014 Mar; 33(3):559-64. PubMed ID: 24366006
[TBL] [Abstract][Full Text] [Related]
6. The purine scaffold Hsp90 inhibitor PU-H71 sensitizes cancer cells to heavy ion radiation by inhibiting DNA repair by homologous recombination and non-homologous end joining.
Lee Y; Li HK; Masaoka A; Sunada S; Hirakawa H; Fujimori A; Nickoloff JA; Okayasu R
Radiother Oncol; 2016 Oct; 121(1):162-168. PubMed ID: 27666928
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies.
Nayar U; Lu P; Goldstein RL; Vider J; Ballon G; Rodina A; Taldone T; Erdjument-Bromage H; Chomet M; Blasberg R; Melnick A; Cerchietti L; Chiosis G; Wang YL; Cesarman E
Blood; 2013 Oct; 122(16):2837-47. PubMed ID: 23943653
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of a red-shifted fluorescence polarization probe for Hsp90.
Moulick K; Clement CC; Aguirre J; Kim J; Kang Y; Felts S; Chiosis G
Bioorg Med Chem Lett; 2006 Sep; 16(17):4515-8. PubMed ID: 16797988
[TBL] [Abstract][Full Text] [Related]
9. PU-H71, a novel Hsp90 inhibitor, as a potential cancer-specific sensitizer to carbon-ion beam therapy.
Li HK; Matsumoto Y; Furusawa Y; Kamada T
J Radiat Res; 2016 Sep; 57(5):572-575. PubMed ID: 27242340
[TBL] [Abstract][Full Text] [Related]
10. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.
Caldas-Lopes E; Cerchietti L; Ahn JH; Clement CC; Robles AI; Rodina A; Moulick K; Taldone T; Gozman A; Guo Y; Wu N; de Stanchina E; White J; Gross SS; Ma Y; Varticovski L; Melnick A; Chiosis G
Proc Natl Acad Sci U S A; 2009 May; 106(20):8368-73. PubMed ID: 19416831
[TBL] [Abstract][Full Text] [Related]
11. PAMAM structure-based multifunctional fluorescent conjugates for improved fluorescent labelling of biomacromolecules.
Wängler C; Moldenhauer G; Saffrich R; Knapp EM; Beijer B; Schnölzer M; Wängler B; Eisenhut M; Haberkorn U; Mier W
Chemistry; 2008; 14(27):8116-30. PubMed ID: 18752247
[TBL] [Abstract][Full Text] [Related]
12. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.
Rouhi A; Miller C; Grasedieck S; Reinhart S; Stolze B; Döhner H; Kuchenbauer F; Bullinger L; Fröhling S; Scholl C
Oncotarget; 2017 Jan; 8(5):7678-7690. PubMed ID: 28032595
[TBL] [Abstract][Full Text] [Related]
13. Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90.
He H; Zatorska D; Kim J; Aguirre J; Llauger L; She Y; Wu N; Immormino RM; Gewirth DT; Chiosis G
J Med Chem; 2006 Jan; 49(1):381-90. PubMed ID: 16392823
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of cell-permeable biotinylated PU-H71 derivatives as tumor Hsp90 probes.
Taldone T; Rodina A; DaGama Gomes EM; Riolo M; Patel HJ; Alonso-Sabadell R; Zatorska D; Patel MR; Kishinevsky S; Chiosis G
Beilstein J Org Chem; 2013; 9():544-556. PubMed ID: 23616796
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of novel fluorescent probes for the molecular chaperone Hsp90.
Llauger-Bufi L; Felts SJ; Huezo H; Rosen N; Chiosis G
Bioorg Med Chem Lett; 2003 Nov; 13(22):3975-8. PubMed ID: 14592488
[TBL] [Abstract][Full Text] [Related]
16. The novel HSP90 inhibitor, PU-H71, suppresses glial cell activation but weakly affects clinical signs of EAE.
Lisi L; McGuire S; Sharp A; Chiosis G; Navarra P; Feinstein DL; Dello Russo C
J Neuroimmunol; 2013 Feb; 255(1-2):1-7. PubMed ID: 23123171
[TBL] [Abstract][Full Text] [Related]
17. PU-H71: An improvement on nature's solutions to oncogenic Hsp90 addiction.
Trendowski M
Pharmacol Res; 2015 Sep; 99():202-16. PubMed ID: 26117427
[TBL] [Abstract][Full Text] [Related]
18. HSP90 inhibitor PU-H71 increases radiosensitivity of breast cancer cells metastasized to visceral organs and alters the levels of inflammatory mediators.
Kale Ş; Korcum AF; Dündar E; Erin N
Naunyn Schmiedebergs Arch Pharmacol; 2020 Feb; 393(2):253-262. PubMed ID: 31522240
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the aminated agarose nanoparticles labeled with fluorescein isothiocyanate.
Zhang LM; Huang JY; Zhang LH; Chu B; Tang SQ
Scanning; 2010; 32(6):361-8. PubMed ID: 20938971
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of fluorescent probes based on the pyochelin siderophore scaffold.
Noël S; Guillon L; Schalk IJ; Mislin GL
Org Lett; 2011 Mar; 13(5):844-7. PubMed ID: 21294578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
